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J. Fung, and T.E. Starzl 
W E recently reported that intestinal transplantation from Lewis (LEW) to Brown Norway (BN) was 
intractable to FK 506 therapy because of a high incidence of 
a graft-versus-host disease (GVHD) syndrome) similar to 
that in the parent to F) hybrid offspring experiments of 
Monchik and Russell.2 However, transplantation in the 
opposite direction (BN to LEW) was highly successful 
without either GVHD or difficult rejection reactions. Ge-
netic analysis did not provide an explanation for the direc-
tional difference, in spite of the fact that genetic factors are 
known to control alloreactions.3 .4 Consequently, we under-
took the experiments herein reported to determine the 
influence on intestinal transplant outcome of 12 donor-
recipient combinations of 4 fully allogeneic rat strains, with 
or without a 2-week induction course of FK 506. The 
outcome indices of rejection and GVHD proved to be 
influenced overwhelmingly by the choice of the recipient 
strain, with the choice of the donor being a far less 
consequential factor. 
MATERIALS AND METHODS 
Intestinal Transplantation 
Animals. Inbred male LEW (RTlI), BN (RTl"). ACI (RTla). 
and PY G (R Tl C) rats weighing 200 to 300 g were purchased from 
Harlan Sprague Dawley Inc (Indianapolis, Ind) and used as donors 
or recipients. All animals were kept in conventional facilities. 
Water and commercial rat chow were provided ad libitum. 
Intestinal Transplant Operation. Under methoxyflurane anesthe-
sia. orthotopic small bowel transplantation (SBTx) was performed 
as described before.5 For convenience, venous drainage was into 
the recipient inferior vena cava, a procedure that has been shown 
in our laboratories6 and elsewhere 7 not to affect the immune 
reactions. The entire small intestine from the ligament of Trietz to 
the ileocecal valve was harvested on a vascular pedicle, consisting 
of the superior mesenteric artery with a piece of aorta and portal 
vein. End-to-side vascular anastomoses hetween the graft aorta and 
recipient infrarenal aorta. and between the graft portal vein and 
recipient vena cava, were hand sewn with 10-0 Novafil suture. The 
entire recipient intestine was removed and enteric continuity was 
restored via proximal and distal end-to-end intestinal anastomoses. 
Immunosuppression. FK 506 was dissolved in HCO-60 and D-
mannitol carrier solvent and was given intramuscularly at a dose of 
0.64 mg/kgld for 14 days starting on the day of intestlflal transplan-
tation. Body weight, activity, skin color. and defecation patterns 
were monitored daily for the first 14 days, and at least twice a week 
thereafter for 150 days. Clinical signs of rejection were defined as 
continuous or intermittent diarrhea and weight loss. GVHD was 
clinically defined by cutaneous erythema. and by hair and weight 
loss. 
Tissue Collection. A complete necropsy was performed on the 
animals that died before 150 days. Pieces of tissue from graft 
intestine, including Peyer's patches. graft and recipient mesenteric 
lymph nodes, spleen, and skin were submitted for pathological 
evaluation. Animals surviving for more than 150 days were used 
either for skin graft experiments or killed to obtain lymphoid 
tissues for in vitro immunologic testing and for histopathologic 
examination. 
Immunologic Testing of Long-Term Survivors 
Skill Grafting. In a subgroup of long-surviving animals. full-
thickness tail skin grafts (1 x 1 cm) were taken from syngeneic 
bowel donor and syngeneic recipient strains and third party rats. 
These were placed on 4 PYG and 4 ACI recipients who had lived 
for 152 to 217 days after small intestinal replacement, having 
received no immunosuppression since the 14th postoperative day. 
The skin grafts were shielded with a plaster cast for 7 days. and 
inspected daily thereafter. Rejection was considered complete 
when no part of the graft remained viable. 
Mixed Lymphocyte Reactions. Cervical lymph node cells col-
lected from 3 ACI and 2 PYG intestinal recipients after 190 to 291 
days were used as responders in one-way mixed lymphocyte 
reactions (MLR). Irradiated (2000 rads) lymphocytes were ob-
tained from the cervical lymph nodes of naive rats of the intestinal 
donor strain, recipient strain, and third parties. Triplicate cultures 
with 1.75 x 1~ responder and 3.0 x 1~ stimulator cells were 
prepared in 96-well round-bottomed microculture plates at a final 
volume of 0.2 mL RPMI-I640 (GIBCO Inc, Grand Island, NY). 
The medium was supplemented with 25 mmollL HEPES buffer. 
5 x 10-5 mol/L 2-mercaptoethanol. 50 UimL penicillin, 50 f.LglmL 
streptomycin, 2 mmol/L L-glutamine, and 1Oo/c normal rat serum. 
The cultures were incubated in a humidified atmosphere of 5'1 
CO2 for 4 days at 37°C. One }.lCi of 3H-thymidine was added to the 
cultures 16 hours prior to read-out with a multiple sample harvester 
(Skatron Inc, Steerling. Va). 'H-thymidine uptake was determined 
by liquid scintillation spectrometry. 
Cell-Mediated Lympholysis. The cytotoxic activity of 4 x 10" 
splenocytes from 2 ACI and 3 PYG intestinal recipients surviving 
for 218 to 421 days was assessed with a standard 5lCr·release 
assay.s The effecto; splenocytes were depleted of B and accessory 
cells by incubation with a nylon wool column for 45 minutes at 
37c C. The effectors were cultured for 5 days in 2.0 mL Dulbecco's 
Modified Eagle Medium (GlBCO Inc) with 4 x 10" irradiated 
(2000 rads) cervical lymph node cells obtained from naive rats of 
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Table 1. Survival Without Immunosuppression in 6 Rat Strains in Which Intestinal Transplantation Was Performed in Both 
Directions (12 Combinations) 
Median Survival' No. No. Survival' 
Median 
14 10, 13, 15, 144 4 ~ ACI to BN 4 7, 8, 9, 88 8.5 
12.5 12.12,11,11 4 <- BN to LEW 6 9,9,10,11,12,14 10.5 
13 13, 13,13 3 LEW to PVG -> 5 5,7,14,19,25 14 
8 6,8, 10 3 PVG to ACI --> 5 10,10,11,11.13 11 
8.5 7, 8, 9, 12 4 ACI to LEW 4 5, 5, 5, 6 5 
12 8, ~I 12, 12, 11 5 <- BN to PVG 3 11,11,13 11 
·Underlined numbers indicate temporary GVHD. 
the bowel donor strain or third party rats. The medium was 
supplemented with 1 mmollL sodium pyruvate, 100 U/mL penicil-
lin. 100 J.Lg'mL streptomycin. 10 mmolfL HEPES buffer. 13.6 
J.LmolfL folic acid. 0.3 mmol/L L-asparagine. 2 mmollL L-glu-
tamine,5 x 10- 5 mol/L 2-mercaptoethanol, 10% fetal calf serum. 
and 0.5 mmoliL NG monomethyl-L-arginine.' 
Targets were prepared by culturing the cervical lymph node cells 
of naive rats of the bowel donor strain or of third party rats with 2 
ILg/mL phytohemagglutinin (DlFCO. Detroit, Mich) for 2 days, 
followed by labeling with 51Cr (New England Nuclear. Boston, 
Mass). The target cells (4 x 103 ) were mixed with effector cells in 
V-bottomed 96-well microtiter wells at ratios of 3: 1, 10: 1.30: I. and 
100:1 and incubated for 6 hours at 37"C. One hundred microliters 
of the supernatant were then removed and 51Cr release measured 
by a gamma radiation counter (Beckman). Cytotoxicity was calcu-
lated according to the following formula: (experimental [cpm) -
background cpm/maximum cpm - background cpm) x 100. Ra-
dioactivity spontaneously released from the target cells in the 
absence of effector cells was defined as the background cpm. and 
maximum cpm was obtained by directly counting 4 x 103 deter-
gent-lysed target cells. 
Pathologic Studies 
Routine. Tissues obtained at necropsy from the intestinal graft 
and mesenteric lymph nodes. recipient spleen, cervical and mesen-
teric lymph nodes, thymus, skin, and liver were fixed in neutral 
buffered formalin, embedded in paraffin, and routinely stained with 
hematoxylin-eosin for blinded histologic examination. without 
knowledge of the experimental group. 
Immunopathologic. An indirect immunoperoxidase technique 
was used to identify positively staining donor cells in ACI recipients 
of PVG grafts (n = 3) and PVG recipients of ACI grafts (n = 2) 
who survived more than 150 days. A separate piece of tissue from 
each site was frozen in ocr compound for immunohistochemical 
studies. The monoclonal antibodies 0X27 and MN4-91-6 (Serotec 
Ltd, Bicester, England), which react with a polymorphic determi-
nant of major histocompatibility complex (MHC) class I on PVG 
(RTl N) and ACI (RTl N), respectively, were used to identify 
cells of donor origin within host tissues. and the presence of host 
cells in the small bowel graft.9.IO An immunoglobulin class-matched 
irrelevant antibody was substituted for the primary antibody as a 
negative staining control. The immunostained slides were exam-
ined without knowledge of the experimental group or primary 
immunoreactant (test antibody or control). 
Statistical Analvses. The significance of differences in intestinal 
recipient and skin graft survival were analyzed with the Log rank 
test. MLR and cell-mediated lympholysis results were analyzed 
with Student's t test. A P value < .01 was considered significant. 
RESULTS 
Survival and Course 
Untreated Rats. Survival in different strain combinations 
ranged from 5 to 14 days (Table 1), the shortest being with 
ACI to LEW. Although survival was not significantly dif-
ferent in most strain pairs with transplantation in either 
direction, a trend toward unbalanced results with a median 
disparity of at least 3 days was present in half of the pairings 
(Table 1). All of the BN recipients of LEW or 4 out of 5 
PYG grafts developed signs of transient skin GYHD be-
tween days 7 and 9 before dying of graft rejection. In other 
strain combinations, the transient dermal erythema was 
seen only in one PYG recipient of a BN intestine. 
One ACI recipient of a BN intestine lived for 144 days, 
and in the other direction of transfer, a BN recipient of an 
ACI intestine survived for 88 days (Table 1). Aside from 
these 2 exceptions, the clinical course was similar in all of 
the other 48 experiments. After an uneventful recovery 
from operation, the animals had progressive diarrhea, body 
weight loss, and death from rejection. 
Treated Rats. The 2-week course of FK 506 improved 
survival in all strain combinations tested when compared 
with the same strain combinations in untreated animals 
(P < .01 overall). However, the magnitude of the survival 
effect shown in Table 2 for individual animals, as well as the 
maintenance of body weight, were profoundly influenced by 
the direction of the graft transfer. For example, BN intes-
tines were accepted and supported nutrition well in virtually 
all PYG and ACI recipients; in LEW recipients survival 
beyond 150 days also was the rule although only 30% of the 
animals could maintain their weight (Table 2). 
In contrast, transplantation from any of these strains to 
the BN recipient led to death after a median time of 32 to 
91 days. However, the cause for the poor outcome with BN 
recipients varied. Those given ACI intestines died of rejec-
tion with a median survival of 91 days, but when PYG or 
LEW donors were used. the invariable cause of death after 
31 to 63 days was GYHD. In contrast, none of the ACI, 
PYG, or LEW recipients of intestines from any of the test 
strains had skin changes. 
An influence of the direction of the transplantation also 
could be seen with the ACI-LEW strain combination, but 
not to the extent as when BN was involved and never with 
the complication of GYHD. In contrast, the LEW-PYG 
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Table 2. Survival Using FK 506 Induction in 6 Strain Combinations With Intestinal Transplantation in One Strain Direction or 
the Other 
Weight' Weight· 
Loss Median Survivalt No. No. Survivalt Median Loss 
0/4 > 150 24*, > 150 x 3 4 <- ACI to BN 5 9*,87,91,104, > 150 91 4/5 
5/5 32 ;tlI~I~I~I~ 5 BN to LEW 10 42,105,107,112, > 150 X 6 > 150 7/10 
2/4 > 150 5*,>150x3 4 <-- LEW to PVG -> 4 10*, > 150 X 3 > 150 0/4 
0/3 > 150 > 150 x 3 3 <- PVG to ACI 4 > 150 x 4 > 150 0/4 
0/5 > 150 11*,>150x4 5 <- ACI to LEW -> 3 85, 133, 143 133 3/3 
717 42 ~I1KOI1OKI1OKI~I44I~ 7 <- BN to PVG -> 7 > 150 x 7 > 150 017 
'Number of animals with weight loss> 10% body weight after completion of 0.64 mg/kg FK 506 for 14 days. 
tUnderiined numbers Indicate animals that died of GVHD. 
'Died of intestinal obstruction without evidence of rejection or GVHD. 
and PVG-ACI combinations were "balanced" in that the 
survival outcome and ability of the grafts to maintain 
nutrition was the same no matter which strain of these pairs 
served as donor or recipient (Table 2). 
These data are categorized in Table 3 in terms of the 
donor and recipient characteristics of each of the 4 strains 
in relation to the other 3. With the group of 4, BN was a 
universal donor whereas PVG and ACI were universal 
recipients. All PVG and ACI recipients survived for more 
than 150 days regardless of the donor strain, except for 3 
rats who died early because of an obstructive ileus. These 
animals were free from any clinical signs of rejection, and 
steadily gained weight throughout the entire observation 
period. 
Immunologic Testing 
Late Skin Graft Challenge. Eight of the "universal recip-
ients" (4 PVG and 4 ACI) of well-functioning intestinal 
allografts from BN. PVG. or ACI donors were given skin 
grafts more than 150 days later from the recipient, intestinal 
donor strain and third party donors (Table 4). Skin grafts 
from third party donors were rejected promptly. Skin grafts 
from the original intestinal donor strain had more than 
doubling of survival (10.5 to 23.5 days) in the 4 PVG 
recipients. and survived permanently in the 4 ACI recipi-
ents (Table 4). 
MLR. All 5 long-surviving recipients were nonresponsive 
to their naive syngeneic lymphocytes but responded nor-
mally to third party stimulation (Fig 1). The PVG recipients 
also responded vigorously to donor strain lymphocy1es, but 
all of the ACI intestinal recipients had reduced reactivity to 
donor strain stimulator cells (Fig 1). 
Cytotoxic T-Lymphocyte Response. The B-cell-depleted 
splenOcy1es of long-surviving PVG recipients did not de-
velop a vigorous cy1otoxic T-Iymphocyte (CfL) response 
either to third party lymphOcy1es or to lymphOcy1es of the 
intestinal donor strain. The CfL responses to donor strain 
and third party stimulation shown in Fig 2 from 2 ACt 
intestinal recipients (experiments) was essentially the same 
using responding lymphocy1es from the chronically surviv-
ing intestinal recipients and from naive recipient strain 
recipients. 
Standard Pathological Studies 
Untreated Rats. The gross and microscopic changes were 
essentially the same as we described before,S with purulent 
ascites. interintestinal adhesions, patchy mural or transmu-
ral necrosis of the bowel allograft, and enlarged mesenteric 
lymph nodes. 
In the 2 exceptional animals with survival of 88 and 144 
days, there was clear histological evidence of chronic rejec-
tion 11 with obliterative arteritis, villous atrophy, and deple-
tion and scarring of the graft Peyer's patches and mesen-
teric lymph. 
Treated Rats. Tissue examination was congruent with the 
clinical impressions in the different strain combinations 
(Table 5). There were changes typical of acute GVHD in 
the skin of the BN recipients of LEW or PVG bowel grafts, 
with a superficial dermal and perivascular mononuclear 
infiltrate. The picture was completed by epidermal exocy-
tosis, satellitosis. keratinocyte necrosis, and spongiosis. The 
Table 3. Summary of Donor and Recipient Characteristics of 4 Rat Strains for Intestinal Transplantation 
1 BN 
2 LEW 
3 PVG 
4 ACI 
As Donor 
'Accepted by PVG (150) and ACI (150); less well by LEW (150) 
Causes GVHD in BN (32); accepted by PVG (150) and ACI (150) 
Causes GVHD in BN (42); accepted by ACI (150) and less well 
by LEW (150) 
Rejected by LEW (133) and BN (91); accepted by PVG (150) 
'Universal donor 
tUnlversal recipient. 
Parentheses indicate days median graft survival. 
As Recipient 
Rejects ACI (91); fatal GVHD caused by PVG and LEW 
Rejects ACI; (133) accepts BN (150) and PVG (150) 
imperfectly 
Accepts alit 
Accepts alit 
T 
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Table 4. Skin Graft Survival After Acceptance of Small Bowel Allografts in PVG and ACI ReCipients 
Recipient Skin Graft Donor Skin Graft Survival (d) Median (d) 
PVG after SBTx (n = 4)" PVG > 100 x 4 > 100.0 
Bowel donor strain 20, 22, 25, 30 23.51 
Third party strains 8,10 x 3, 11 x 3, 13 10.5 
ACI after SBTx (n = 4)* ACI > 100 x 4 > 100.0 
Bowel donor strain > 100 x 4 > 100.0t 
, 
Third party strains 9, 10 x 4, 11 x3 10.0 
'ACI (n = 1) and BN (n = 3) donor. . 1 
tSkin graft survival prolonged (P < .01). Normal PVG rats reiected LEW, BN, and ACI skin grafts with median survival of 11.5,10.0, and 10.0 days, respectively 
(n = 4 each group). Median LEW, BN, and PVG skin graft survival in normal ACI recipients was 10.0 days (n = 4 each group). 
tpVG (n = 2) and BN (n = 2) donor. 
bowel allografts were normal in these animals in contrast to 
the BN recipients of ACI intestines in which the findings of 
chronic rejection were unequivocal (Table 5). 
Although a far better survival record was compiled 
clinically with the LEW (9 of 17 > 150 days) than the BN 
recipients (1 of 17 > 150 days), the late pathology was the 
same. Obliterative arteriopathy and the other stigmas of 
chronic rejection were found in the intestines of the LEW 
recipients, regardless of the donor strain. 
ACI and PVG recipients of all strains of intestines 
appeared clinically equivalent in terms of long survival and 
weight gain. However, pathologic examination of their 
allografts after 150 days revealed a difference between these 
2 cohorts of apparently healthy intestinal recipients. Graft 
lymphoid tissues were mildly atrophic or scarred in PVG 
recipients, in contrast to minimal alteration in ACI recipi-
ents. Obliterative arteriopathy was rare or absent in both 
ACI and PVG recipients, no matter what the donor strain. 
A 
1:5000 
~ ,.I 10000 
:5000 
~ 
-
The pathologic findings suggested that the PVG recipients 
were slowly rejecting their grafts, whereas the ACI recipi-
ents appeared to be completely spared from this process. 
Immunohistochemical Studies 
ACI Recipients. Tissues from the three ACI recipients of 
PVG grafts were stained for cells bearing the PVG pheno-
type (OX27) at 343, 421, and 506 days after transplantation. 
The endothelial cells, epithelial cells, and rare lymphoid 
cells within the Peyer's patches within the graft remained 
donor phenotype, while the vast majority of cells in the 
Peyer's patches were OX27-negative. When the immuno-
stained slides of recipient lymphoid tissues were reviewed 
without knowledge of the primary immunoreactant, the 
presence of positively staining cells correlated with the use 
of 0X27 as the primary immunoreactant in more than 75% 
of tissue samples, supporting the diagnosis of microchimer-
ism. 
B 
f' 
b' .I 
I, 
.. 
Fig 1. One-way MLR, using cer-
vical lymph node lymphocytes of 
naive and chronically surviving 
PVG or ACI intestinal recipients 
as responding cells with stimula-
tion by irradiated cervicallympho-
cytes from unaltered recipient 
(syngeneic) strain (l1li, first bar), 
intestinal donor strain ([l, middle 
bar), and third party strain ~I 
third bar). In each double panel 
(A-E) , the activation of the re-
sponding naive recipient strain 
lymphocytes is on the left, and 
that of the intestinal recipient's 
lymphocytes is on the right. Mean 
cpm ::': SD of triplicate cultures. 
(A) PVG recipient of BN bowel. (B) 
PVG recipient of LEW bowel. (e) 
ACI recipient of BN bowel. (D) ACI 
recipient of LEW bowel. (E) ACI 
recipient of PVG bowel. .3H-thy-
midine uptake significantly lower 
(P < .01) than with lymphocytes 
of normal animal to the same 
stimulator cells. 
nonnaJ PVG lIan'pianled PYG nontlOll PYG lran!pl3l1ted PVG 
origin or responder cells 
10000 
c D 1-
,I 1 
10000 
I" 
.. J 
'---
I' . J , w.""" 
ncnnal ACI lranspiamed ACI normal ACI lransplanted ACI nonnaiACI It>I1Splanl<d ACI 
origin of responder cells 
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ACI recipient or LEW bowel gran ACI recipient or PVG bowel graft 
A 60 C 60 
.s BN (third party strain) 
50 50 
J:> 40 J:> 40 'v :~ 30 'g 30 ~ g 
"0 " 20 20 ~~ " 
I;t 10 I;t 10 
0 0 
·10 -10 
3:1 \0:1 30:1 100:1 
B 60 D 60 PI LEW (bowel graft strain) 50 
.., 
.., 40 ~ '0 '0 -g 'g 30 .. S ;; S 20 ~ » " ... 10 I;t I;t 
0 
·10 
3:1 10:1 30:1 100:1 
E;T ratio 
--6-- ACI of LEW bowel mfl --+- nonnal ACI 
PVC Recipients. Tissues from 2 PVG recipients of ACI 
grafts were stained for cells bearing the ACI phenotype 
(MN4-91-6) at 153 and 517 days posttransplantation. In the 
animal killed at 153 days, the graft mesenteric lymph nodes 
were enlarged because of scarring, but endothelial (epithe-
lial) and stromal cells remained donor origin. The rat killed 
at 517 days did not show scarring of the graft mesenteric 
lymph nodes or Peyer's patches. MN4-91-6+ (donor) cells 
were identified more often in the tissue sections stained 
Table 5. Pathological Findings· in the Small Bowel Grafts 
Following a 2-Week Course of FK 506 
Strain Combination Pathological Findings of the Graft 
Mesentenc 
Peyer's Lymph Obliterative 
Recipient Donor Mucosa' Patches' Nodes' Arteriopathy 
BN LEW 0 0 0 0 
BN PVG 0 0 0 0 
BN ACI 2 1-2 0-2 
LEW ACI 2 2 0-1 
LEW BN 2 0-1 
LEW PVG 0 1-2 0-2 
PVG LEW 0 0 0-1 0 
PVG ACI 0 0 0-1 0 
PVG BN 0 0 0-1 0 
ACI LEW 0 0 0 0 
ACI BN 0 0 0 0 
ACI PVG 0 0 0 0 
'T,ssues from animals who died before 150 days or those surviving 150 to 
506 days after small bowel transplantation. 
'Blunting of villi, cryptitis, and lymphoid depleted lamina propria. 
'Lymphoid depletion and fibrosis. 
Diagnosis was classified histologically as 0, nothing - rare; 1, present; 2. 
severe. Two to four animals were examined .n each donor-recipient combina-
tion. 
3:1 10:1 30:\ 100:1 
OJ PVG (bowel graft strain) 
Fig 2. Cytolytic activity of the 
splenocytes from long-surviving 
ACI recipient of (A, B) LEW 
(open triangles) or (C, 0) PVG 
(open circles) bowel graft. Iso-
lated splenocytes were cultured 
with irradiated donor or third 
party strain lymphocytes for 5 
days. Cytolytic function against 
the (B, 0) bowel graft and (A, C) 
third party strain target cells 
was assessed in a standard 
s'Cr-release assay. Bars and 
circles/triangles represent mean 
::': SD of triplicate cultures. The 
closed circles represent the per-
cent cytotoxicity of normal ACI 
rat splenocytes. 
3:1 10:1 30:1 100:1 
E;T ratio 
~ ACI of PVG bowel ~rafi 
with MN4-91-6 than in the appropriate negative controls. 
The findings in these PVG recipients were consistent with 
microchimerism, but this diagnosis could not be made 
conclusively with only 2 animals available for study and the 
sparse number of ACI-positive cells. 
DISCUSSION 
In our recent study,1 we cited evidence from the literature 12 
as well as from our own observations in heart, liver. and 
intestinal recipients"·11 (and unpublished observation) that 
the BN rat was a universal donor. However, when grafting 
was done the other way around under FK 506. BN recipi-
ents of LEW intestines almost invariably developed 
GVHD, I similar to observations using cyclosporine by 
DeBruin et al 13 with WAG (RTIU) to BN. The GVHD 
syndrome resembled that of the classical parent to F J hybrid 
experiments of Monchik and Russell." However. because 
BN to LEW and LEW to BN experiments did not yield 
mirror image results, these could not fit into the same 
conventional genetic analyses. I 
In our earlier report.! the disparate data could not be 
explained by the responder versus nonresponder classifica-
tion of the BN and LEW rats, the Jymphocy1e subpopula-
tions of the respective strains, the in vitro reactivity of these 
strains (each to the other) with or without FK 506 culture 
enrichment, or differences in the traffic or density of donor 
passenger leukocytes in recipient lymphoid organs out to 40 
days. The most solid clue was evidence in BN rats of a 
defect in the invariant chain of MHC class II molecules l •14 
with the implication that this could lead to inefficient 
processing of donor antigen without necessarily implying 
immune abnormalities in this strain. 15.16 
Nevertheless, the GVHD propensity of the BN intestinal ! i 
I 
: 
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Table 6. Recipient Survival After Fully Allogeneic Small Bowel 
Transplantation Without Immunosuppression 
(Published Through 1993) 
of antinuclear antibodies, immune glomerulonephritis, en-
hanced class II MHC expression on B-cells, increased 
serum immunoglobulin (Ig)G and IgE, elevated interleukin 
(IL)-4 activity, and impairment of IL-2 production. 17-23 The 
cytokine profile observed suggests that an active 111 2-type 
immune response may be important in the pathogenesis of 
all these manifestations.24 The possibility is under investi-
gation that an autoimmune reaction after transplantation 
secondary to the ubiquitous distribution of donor hema-
tolymphoid cells could playa role in fostering graft accep-
tance or allowing a fatal GVHD after intestinal transplan-
tation. 
Strain 
Combinations 
Recipient Donor 
LEW ACI 
LEW BN 
LEW F334 
BN LEW 
BN WAG 
WAG BN 
WFu BUF 
PVG DA 
DA LEW 
Survival (d) Reference(s) 
7.0-12.0 39.41.42.45.47 
6.8-13.0 1.2.5.6,11,38.39.41,42.46.48 
9.5 40 
10.7-12.0 1.2 
12.8-32.0 13. 49. 50. 52 
12.2 13. 50 
10.5 48 
7.3-18.6 42.44. 51 
6.6 43 
recipient could imply subtle immunologic perturbations, a 
possibility strengthened by collateral evidence. For exam-
ple, the BN rat strain carrying the RTl n haplotype and 
derived strains are exquisitely sensitive to the induction of 
autoimmunity precipitated by treatment with mercuric 
chloride, gold salts, or D-penicillamineY-20 They are also 
highly permissive of the trafficking in their tissues of many, 
but not all. strains of allogeneic lyrnphocytes.21 In fact, 
autoimmune reactions similar to those precipitated by 
heavy metals can also be triggered in BN rats and certain 
mice strains by an allogeneic GVH reaction.22•23 The 
characteristics of this autoimmunity include the production 
Beyond confirming that BN was the only universal donor 
among the 4 strains used, the present study also showed that 
the choice of recipient strain dominated the outcome in all 
combinations tested (Table 3). Following a 2-week course 
of FK 506, the LEW recipient did not accept any strain 
intestine unreservedly, although it may be inferred that 
longer treatment would have allowed lifetime survival with 
BNIl and probably also PVG and ACI bowel. In contrast, 
ACI and PVG rats were universal recipients by clinical 
criteria under the short-term treatment conditions of these 
experiments. The ACI recipients had in vitro findings of 
obtunded but not absent donor recipient reactivity, as well 
as the ability to permanently accept donor skin grafts. Their 
allograft intestines were essentially normal and they had 
convincing evidence of microchimerism. 
The PVG recipients whose clinical course was not per-
Table 7. Recipient Survival After Fully Allogeneic Small Bowel Transplantation With Immunosuppression (Published Through 1993) 
Strain Combinations 
Recipient Donor Immunosuppression Survival (d) Reterence(s) 
LEW ACI CyA 15 mg/kgld, 1M (d 0->28) 130.3 39 
CyA 40 mg/kgld, 1M (d -2->7) 34.3 47 
FK 506 0.1-0.5 mglkgld, 1M (d 0->29) 13.6-34.6 45 
FK 506 2.0->1.0 mg/kgld, 1M (d 0->30) 50.6 47 
LEW BN CyA 5 mg/kgld, 1M (d 0->13) > 100 41 
CyA 15 mglkgld, 1M (d 0->28) > 360 38.39 
CyA 15 mg/kg/d, 1M (d 0->6) > 200 53 
FK 506 0.15 mglkg/d, 1M (d 0->13) 42.0 
FK 506 0.32-0.64 mg/kg/d, 1M (d 0->13) > 100 1,6. 11 
FK 506 2.0 mg/kg/d. 1M (d 0->4) > 180 38 
RS 61443 30 mg/kg/d, PO (d 0->6) 10.7 46 
Rapamycin 0.8-1.6 mg/kg/d. civ (d 0-> 13) 21.6-31.0 48 
LEW F344 CyA 30 mg/kgld. 1M (d 0-> 13) > 150 40 
FK 506 0.32 mg/kg/d, 1M (d 0->13) > 150 40 
Deoxyspergualin 3 mg/kg/d. 1M (d 0->11) > 80 40 
BN LEW FK 506 0.15-1.0 mglkg/d, 1M (d 0->13) 22.5-28.5 (GVHD) 
BN WAG CyA 5-25 mg/kg/d. 1M (d 0, 1. 2. 4. 6) 18.7-92.7 (GVHD) 13.50 
FK 506 2.0 mg/kg/d, 1M (d 0,1,2.4,6) 28.5 (GVHD) 49 
Rapamycin 1.0 mg/kg/d, 1M (d 0, 1, 2, 4. 6) 10.0 50 
WAG BN CyA 5-25 mg/kgld, 1M (d 0, 1, 2, 4, 6) 9.6-200 13 
Rapamycin 1.0 mglkg/d, 1M (d 0, 1, 2, 4, 6) 11.3 50 
WFu BUF Rapamycin 0.8 mglkgld, civ (d 0->13) 25.0 48 
PVG DA CyA 15 mg/kgld, 1M > 100 44 
DA PVG CyA 15 mg/kgld. PO > 56 54 
Abbreviations: CyA. cyclosporine A; 1M. intramuscular injection; PO. oral admInistration; civ. continuous intravenous infusion. 
1 
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ceptably different than ACI did not have a donor-specific 
defect on MLR, and had delayed rejection of donor skin. 
Systemic microchimerism was minimal, and the intestines 
had histopathologic findings suggesting subclinical early 
rejection. Considering the lifespan of rats, the biologic 
differences between the ACI and PVG recipients may prove 
to be insignificant. The discordance in both the ACI and 
PVG recipients between in vivo and in vitro indicators of 
tolerance ('"split tolerance") has been observed before in 
neonatal chimeras25 and after organ transplantation under 
cyclosporine,26.27 FK 506,28 monoclonal antibodies,29 and 
as a natural consequence of liver grafting?o.31 
The superiority of the ACI recipient can be explained by 
the previously reported genetically controlled hyporespon-
siveness that could be quantitated by in vitro testing.3.4 
These tests showed weak alloantibody production and 
ineffectual cytotoxicity against donor antigens after immu-
nization with lymphocyte injections. Such unresponsiveness 
could also be used to explain why only ACI donors did not 
mount vigorous GVH reactions and therefore permitted 
consistently long survival (median 91 days) without GVHD 
in the relatively defenseless BN recipient. However, this 
argument (in both strain direction) loses force by the fact 
that other successful or semisuccessful strain combinations 
did not depend either on a low responding donor, recipient, 
or either for avoidance of GVHD. Instead, we have postu-
lated elsewhere 14 .32 that a balance without the emergence 
of dominance of 1 cell population must be accomplished 
between the coexisting cell popUlations for successful allo-
transplantation. particularly for organs with a heavy constit-
uency of passenger leukocytes. 
Different lines of inquiry may be needed than those 
pursued in the past to learn how this cellular balance is 
accomplished with or without the aid of immunosuppres-
sion. Little attention has been given to the role that 
alloreactive NK cells33.34 or other natural cytotoxicity mech-
anisms may have in solid organ transplantation biology.35.36 
Such non-T cells are genetically defined, facilitate or inhibit 
allogeneic progenitor cell engraftment,35 and are responsi-
ble for the rapid elimination within hours of mature allo-
geneic lymphocytes, long before classical allogeneic immu-
nity comes into play.36 Consistent with this line of 
reasoning. Sheng-Tanner and Miller37 have shown that 
anti-NK cell therapy fosters the development of hema-
tolymphoid chimerism and prolongs the survival of al-
lografts. 
It will be useful for other investigations of intestinal 
transplantation to have a catalogue of strain combinations 
with and without immunosuppression. Our study provided 
12 in the treatment as well as in the non treatment category, 
each including 5 combinations already reported by us or 
others. Thus. we have added 7 to both groups. There have 
been 4 additional strain combinations in the 2 categories, 
adding up at present to a total of 16 in each. This frame-
work of previously published and new information is sum-
marized in Tables 6 and 7. 
3739 
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